Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.55 |
| ▸ | HPGD | P15428 | 8/20 | 0.51 |
| ▸ | HTT | P42858 | 4/20 | 0.51 |
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | RECQL | P46063 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.50 |
| ▸ | TSHR | P16473 | 4/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.50 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.50 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.50 |
| ▸ | TNKS | O95271 | 1/20 | 0.48 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL32664934 | 0.88 | ALDH1A1 (0.56) | KDM4EALDH1A1SMN1; SMN2HPGDHTT | |
| SCHEMBL14852007 | 0.85 | HPGD (0.53) | KDM4EALDH1A1SMN1; SMN2HPGDHTT | |
| SCHEMBL15365749 | 0.85 | HSD17B10 (0.58) | KDM4EALDH1A1SMN1; SMN2HPGDHTT | |
| SCHEMBL4784567 | 0.84 | BRD4 (0.65) | KDM4EALDH1A1SMN1; SMN2HPGDHTT | |
| SCHEMBL16456310 | 0.84 | KDM4E (0.49) | KDM4EALDH1A1SMN1; SMN2HPGDHTT | |
| SCHEMBL16455949 | 0.84 | ALDH1A1 (0.50) | KDM4EALDH1A1SMN1; SMN2HPGDHTT | |
| SCHEMBL15364726 | 0.84 | ALDH1A1 (0.66) | KDM4EALDH1A1SMN1; SMN2HPGDHTT | |
| SCHEMBL24401671 | 0.82 | DPP4 (0.54) | KDM4EALDH1A1SMN1; SMN2HPGDHTT | |
| SCHEMBL14765168 | 0.81 | KDM4E (0.64) | KDM4EALDH1A1SMN1; SMN2PIM1 | |
| SCHEMBL32665254 | 0.80 | ALDH1A1 (0.51) | KDM4EALDH1A1SMN1; SMN2HPGDHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260022124-A1 | THERAPEUTIC COMPOUNDS AND METHODS | UNIV MINNESOTA (US) | 2026-01-22 | — | — | US | disclosed |
| US-9340549-B2 | Oxazolidinone compounds and derivatives thereof | AMGEN INC. (US) | 2016-05-17 | — | — | US | disclosed |
| US-20150246902-A1 | SUBSTITUED BENZOFURAN COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. (US) | 2015-09-03 | — | — | US | disclosed |
| US-20150045368-A1 | OXAZOLIDINONE COMPOUNDS AND DERIVATIVES THEREOF | AMGEN INC. | 2015-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260022124-A1 | THERAPEUTIC COMPOUNDS AND METHODS | NR5A1, CYP17A1, CNR1 | KDM4E 1972/4885ALDH1A1 663/4885SMN1; SMN2 3155/4885 |
| US-20150045368-A1 | OXAZOLIDINONE COMPOUNDS AND DERIVATIVES THEREOF | TNKS1BP1, TNKS, TBKBP1 | KDM4E 1142/4885ALDH1A1 1646/4885SMN1; SMN2 3293/4885 |
| US-20150246902-A1 | SUBSTITUED BENZOFURAN COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | EIF5B, EIF2AK2, HCCS | KDM4E 2423/4885ALDH1A1 158/4885SMN1; SMN2 1500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.